Hanlim Pharmaceutical launched the improvement product of the xerophthalimia treatment ‘Restasis Eye Drop’ for the first time in Korea
Hanlim Pharm (CEO Jae-yoon Kim) completed developing an improved product of the xerophthalimia treatment ‘Restasis Eye Drop’ (generic name: Cyclosporine) for the first time in Korea, and launched it with the title named ‘Tsporine Eye Drop’.
Hanlim Pharm acquired the Investigational New Drug (IND...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
